Metabolic comorbidity in schizophrenia.

People with schizophrenia are at greater risk of developing obesity, type 2 diabetes, hypertension and dyslipidemia as compared to the general population. This results in an increased incidence of cardiovascular disease, leading to greater morbidity and mortality in this vulnerable group of patients. Use of certain antipsychotic agents can compound this risk and increase the risk of developing metabolic syndrome. Appropriate identification and management of these risk factors are very important in reducing the risk and thereby improving the physical health of these patients. This review recommends a framework based on existing guidelines for the assessment, monitoring and management of patients with schizophrenia in the Indian setting.